메뉴 건너뛰기




Volumn 8, Issue 6, 2010, Pages 739-741

Out with the old, in with the new: An updated risk stratification equation for pulmonary arterial hypertension

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANOREXIGENIC AGENT; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST; WARFARIN; ANTIHYPERTENSIVE AGENT;

EID: 77953499336     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.65     Document Type: Editorial
Times cited : (2)

References (22)
  • 1
    • 64849109410 scopus 로고    scopus 로고
    • ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the american college of cardiology foundation task force on expert consensus documents and the American heart association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; And the Pulmonary Hypertension Association
    • McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.53 , Issue.17 , pp. 1573-1619
    • McLaughlin, V.V.1    Archer, S.L.2    Badesch, D.B.3
  • 2
    • 0025837793 scopus 로고
    • Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
    • D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
    • (1991) Ann. Intern. Med. , vol.115 , Issue.5 , pp. 343-349
    • D'Alonzo, G.E.1    Barst, R.J.2    Ayres, S.M.3
  • 3
    • 0023615359 scopus 로고
    • Primary pulmonary hypertension. A national prospective study
    • Rich S, Dantzker R, Ayres S et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 107, 216-223 (1987). (Pubitemid 17137857)
    • (1987) Annals of Internal Medicine , vol.107 , Issue.2 , pp. 216-223
    • Rich, S.1    Dantzker, D.R.2    Ayres, S.M.3
  • 4
    • 0028218793 scopus 로고
    • Survival in primary pulmonary hypertension. Validation of a prognostic equation
    • Sandoval J, Bauerle O, Palomar A et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89, 1733-1744 (1994).
    • (1994) Circulation , vol.89 , pp. 1733-1744
    • Sandoval, J.1    Bauerle, O.2    Palomar, A.3
  • 6
    • 0037441640 scopus 로고    scopus 로고
    • Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol
    • Kuhn KP, Byrne DW, Arbogast PG et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am. J. Respir. Crit. Care Med. 167(4), 580-586 (2003).
    • (2003) Am. J. Respir. Crit. Care Med. , vol.167 , Issue.4 , pp. 580-586
    • Kp, K.1    Byrne, D.W.2    Arbogast, P.G.3
  • 7
    • 33746827371 scopus 로고    scopus 로고
    • Survival in patients with pulmonary arterial hypertension treated with first-line bosentan
    • McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 36(Suppl. 3), 10-15 (2006).
    • (2006) Eur. J. Clin. Invest. , vol.36 , Issue.SUPPL. 3 , pp. 10-15
    • McLaughlin, V.V.1
  • 8
    • 0037126044 scopus 로고    scopus 로고
    • Survival in primary pulmonary hypertension: The impact of epoprostenol therapy
    • McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106(12), 1477-1482 (2002).
    • (2002) Circulation , vol.106 , Issue.12 , pp. 1477-1482
    • McLaughlin, V.V.1    Shillington, A.2    Rich, S.3
  • 9
    • 13844280943 scopus 로고    scopus 로고
    • Survival with first-line bosentan in patients with primary pulmonary hypertension
    • McLaughlin VV, Sitbon O, Badesch DB et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. 25(2), 244-249 (2005).
    • (2005) Eur. Respir. J. , vol.25 , Issue.2 , pp. 244-249
    • McLaughlin, V.V.1    Sitbon, O.2    Badesch, D.B.3
  • 10
    • 33645243403 scopus 로고    scopus 로고
    • Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
    • Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 27(5), 589-595 (2006).
    • (2006) Eur. Heart J. , vol.27 , Issue.5 , pp. 589-595
    • Provencher, S.1    Sitbon, O.2    Humbert, M.3    Cabrol, S.4    Jais, X.5    Simonneau, G.6
  • 11
    • 33646269035 scopus 로고    scopus 로고
    • Pulmonary arterial hypertension in France: Results from a national registry
    • Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006).
    • (2006) Am. J. Respir. Crit. Care Med. , vol.173 , Issue.9 , pp. 1023-1030
    • Humbert, M.1    Sitbon, O.2    Chaouat, A.3
  • 12
    • 37549033243 scopus 로고    scopus 로고
    • A USA-based registry for pulmonary arterial hypertension: 1982- 2006
    • Thenappan T, Shah SJ, Rich S et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur. Respir. J. 30(6), 1103-1110 (2007).
    • (2007) Eur.Respir. J. , vol.30 , Issue.6 , pp. 1103-1110
    • Thenappan, T.1    Shah, S.J.2    Rich, S.3
  • 13
    • 77951961897 scopus 로고    scopus 로고
    • Contemporary survival in patients with pulmonary arterial hypertension: A reappraisal of the National Institutes of Health risk stratification equation
    • Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Contemporary survival in patients with pulmonary arterial hypertension: a reappraisal of the National Institutes of Health risk stratification equation. Eur. Respir. J. 35(5), 1079-1087 (2009).
    • (2009) Eur. Respir. J. , vol.35 , Issue.5 , pp. 1079-1087
    • Thenappan, T.1    Shah, S.J.2    Rich, S.3    Tian, L.4    Archer, S.L.5    Gomberg-Maitland, M.6
  • 14
    • 47049107136 scopus 로고    scopus 로고
    • Pulmonary hypertension in Switzerland: Treatment and clinical course
    • Fischler M, Speich R, Dorschner L et al. Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med. Wkly 138(25-26), 371-378 (2008).
    • (2008) Swiss Med. Wkly , vol.138 , Issue.25-26 , pp. 371-378
    • Fischler, M.1    Speich, R.2    Dorschner, L.3
  • 15
    • 34250870730 scopus 로고    scopus 로고
    • Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines
    • Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6), 1917-1928 (2007).
    • (2007) Chest , vol.131 , Issue.6 , pp. 1917-1928
    • Badesch, D.B.1    Abman, S.H.2    Simonneau, G.3    Rubin, L.J.4    McLaughlin, V.V.5
  • 16
    • 0037151645 scopus 로고    scopus 로고
    • Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival
    • Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40(4), 780-788 (2002).
    • (2002) J. Am. Coll. Cardiol. , vol.40 , Issue.4 , pp. 780-788
    • Sitbon, O.1    Humbert, M.2    Nunes, H.3
  • 17
    • 27744444638 scopus 로고    scopus 로고
    • Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
    • Sitbon O, McLaughlin VV, Badesch DB et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60(12), 1025-1030 (2005).
    • (2005) Thorax , vol.60 , Issue.12 , pp. 1025-1030
    • Sitbon, O.1    McLaughlin, V.V.2    Badesch, D.B.3
  • 19
    • 75249089553 scopus 로고    scopus 로고
    • Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed
    • Macchia A, Marchioli R, Tognoni G et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am. Heart J. 159(2), 245-257 (2010).
    • (2010) Am. Heart J. , vol.159 , Issue.2 , pp. 245-257
    • MacChia, A.1    Marchioli, R.2    Tognoni, G.3
  • 20
    • 20544448927 scopus 로고    scopus 로고
    • Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
    • Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005).
    • (2005) Circulation , vol.111 , Issue.23 , pp. 3105-3111
    • Sitbon, O.1    Humbert, M.2    Jais, X.3
  • 21
    • 0037331116 scopus 로고    scopus 로고
    • Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
    • Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123(2), 344-350 (2003).
    • (2003) Chest , vol.123 , Issue.2 , pp. 344-350
    • Kawut, S.M.1    Taichman, D.B.2    Archer-Chicko, C.L.3    Palevsky, H.I.4    Kimmel, S.E.5
  • 22
    • 33749329543 scopus 로고    scopus 로고
    • Clinical differences between idiopathic and scleroderma-related pulmonary hypertension
    • Fisher MR, Mathai SC, Champion HC et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 54(9), 3043-3050 (2006).
    • (2006) Arthritis Rheum. , vol.54 , Issue.9 , pp. 3043-3050
    • Fisher, M.R.1    Mathai, S.C.2    Champion, H.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.